KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Equity Income (2016 - 2025)

Jazz Pharmaceuticals has reported Equity Income over the past 10 years, most recently at -$57000.0 for Q4 2025.

  • Quarterly results put Equity Income at -$57000.0 for Q4 2025, down 256.25% from a year ago — trailing twelve months through Dec 2025 was -$206000.0 (up 87.59% YoY), and the annual figure for FY2025 was -$732000.0, up 55.9%.
  • Equity Income for Q4 2025 was -$57000.0 at Jazz Pharmaceuticals, down from -$47000.0 in the prior quarter.
  • Over the last five years, Equity Income for JAZZ hit a ceiling of $4.2 million in Q1 2021 and a floor of -$4.1 million in Q1 2022.
  • Median Equity Income over the past 5 years was -$461000.0 (2023), compared with a mean of -$815473.7.
  • Biggest five-year swings in Equity Income: surged 2188.46% in 2021 and later tumbled 616.67% in 2025.
  • Jazz Pharmaceuticals' Equity Income stood at -$3.0 million in 2021, then skyrocketed by 74.13% to -$773000.0 in 2022, then skyrocketed by 40.36% to -$461000.0 in 2023, then soared by 96.53% to -$16000.0 in 2024, then tumbled by 256.25% to -$57000.0 in 2025.
  • The last three reported values for Equity Income were -$57000.0 (Q4 2025), -$47000.0 (Q3 2025), and -$86000.0 (Q2 2025) per Business Quant data.